PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: NC Research Campus

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

JC Med Launches with New Insulin Resistance Products - JC Med, a start-up biotech company, launched operations at the NC Research Campus (NCRC) in Kannapolis, NC, just outside of Charlotte, to produce insulin resistance supplements and to develop a first-of-its-kind, in-home insulin resistance meter
JC Med Launches with New Insulin Resistance Products

 

NewswireToday - /newswire/ - Kannapolis, NC, United States, 2013/12/18 - JC Med, a start-up biotech company, launched operations at the NC Research Campus (NCRC) in Kannapolis, NC, just outside of Charlotte, to produce insulin resistance supplements and to develop a first-of-its-kind, in-home insulin resistance meter.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Founder Wenhong Cao, MD, who is also a research associate professor in nutrition with the UNC Chapel Hill Nutrition Research Institute at the NCRC, has spent his career researching obesity and diabetes. With that knowledge, he has developed a dietary supplement to prevent insulin resistance that is initially being marketed in China through Shanghai Ideal Biotechnology, LLC. The profits from the supplements will fund the continued development of an in-home insulin resistance meter.

Insulin resistance or hyperglycemia is a condition where the body does not use the hormone insulin efficiently. As part of digestion, insulin is released from the pancreas to break down carbohydrates and fats in foods, and convert them to glucose. Insulin also assists cells in the absorption of glucose, which is an energy source. When the human body can no longer produce enough or absorb it efficiently, insulin resistance can result. For many, insulin resistance is a precursor to diabetes and a factor in the development of diseases like Alzheimer’s, fatty liver and other metabolic disorders.

“No one is treating insulin resistance,” Cao said. “Insulin resistance is evident up to 15 years before progressing to diabetes or any other disease. So there is a large window of time to make dietary changes, increase exercise or take supplements or some type of medication. By the time you have diabetes, the damage is done, and you can only manage it. There is no cure.”


About the NC Research Campus
The NC Research Campus is a 350-acre campus in Kannapolis, NC, just north of Charlotte, which is home to corporate, academic and healthcare partners focused on advancing science at the intersection of human health, agriculture and nutrition. Research and product development primarily focuses on breeding healthier fruits and vegetables, developing more effective functional food products and targeting new plant-based therapeutic and personalized approaches to the prevention and treatment of disease. The NCRC has a million square feet of lab and office space under management that includes five buildings and the research power of nine world-renowned universities and colleges in North Carolina. In addition to the university presence, the NCRC is home to General Mills, Sensory Spectrum, Monsanto, LabCorp, Dole Foods, Inc. and JC Med, LLC.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NC Research Campus

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


JC Med Launches with New Insulin Resistance Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Phyllis Beaver - NCResearchCampus.net 
704-250-5436 pbeaver[.]ncresearchcampus.net
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NC Research Campus securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NC Research Campus / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)